• Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact
  • Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact

  • All
  • Press Releases
  • News Articles
    • Press Releases
    February 07, 2022

    Immusoft to Present at WORLDSymposium™ 2022 Conference

    Read More

    Christiane Hampe, Ph.D., Senior Director of Research, will present preclinical data on Immusoft’s Immune System Programming Platform SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2022 Conference,…

    • Press Releases
    November 29, 2021

    Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)

    Read More

    SAN FRANCISCO–(BUSINESS WIRE)– Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP- 002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options.

    • News Articles
    MedCity News | October 13, 2021

    Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft

    Read More
    • News Articles
    Bloomberg | October 13, 2021

    Takeda to Work With Immusoft in $900 Million Rare-Disease Deal

    Read More
    • News Articles
    Endpoints News | October 13, 2021

    Drawn to the idea of turning B cells into ‘protein factories,’ Takeda jumps into a milestone-heavy, $900M pact

    Fierce Biotech

    Read More
    • News Articles
    FIERCE Biotech | October 13, 2021

    Takeda bets up to $900M on Immusoft’s cell therapies for neurometabolic disorders

    Read More
    • Press Releases
    October 13, 2021

    Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

    Read More

    Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies

    • Press Releases
    June 23, 2021

    Immusoft Announces Formation of Scientific Advisory Board

    Read More

    Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.

    • Press Releases
    May 12, 2020

    Immusoft to Present at ASGCT 23rd Annual Meeting

    Read More

    – Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass – Seattle, Wash.–(BUSINESS WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual…

    • Press Releases
    February 05, 2020

    Immusoft to Present at WORLDSymposium™ 2020

    Read More

    – Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform – Seattle, Wash.–(BUSINESS WIRE) –February 5, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced that Scott McIvor, Ph.D., Chief Development Officer, and Professor Genetics, Cell Biology, and…

  • Newer posts
  • Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact

© IMMUSOFT 2022 | 454 N 34th St., Seattle, WA 98103 | Directions | info@immusoft.com